Hutchinson Capital Management CA decreased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 53,641 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Pfizer accounts for about 0.5% of Hutchinson Capital Management CA’s investment portfolio, making the stock its 25th biggest position. Hutchinson Capital Management CA’s holdings in Pfizer were worth $1,802,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Pinnacle Financial Partners Inc. increased its holdings in shares of Pfizer by 36.2% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 120,651 shares of the biopharmaceutical company’s stock worth $4,053,000 after purchasing an additional 32,089 shares during the period. United Asset Strategies Inc. increased its holdings in shares of Pfizer by 3.0% during the 2nd quarter. United Asset Strategies Inc. now owns 80,749 shares of the biopharmaceutical company’s stock worth $2,712,000 after purchasing an additional 2,352 shares during the period. Advisors Asset Management Inc. increased its holdings in shares of Pfizer by 6.2% during the 2nd quarter. Advisors Asset Management Inc. now owns 1,867,923 shares of the biopharmaceutical company’s stock worth $62,744,000 after purchasing an additional 109,478 shares during the period. Signature Financial Management Inc. increased its stake in Pfizer by 23.2% in the second quarter. Signature Financial Management Inc. now owns 30,697 shares of the biopharmaceutical company’s stock valued at $1,032,000 after acquiring an additional 5,774 shares during the period. Finally, Dividend Assets Capital LLC increased its stake in Pfizer by 15.1% in the second quarter. Dividend Assets Capital LLC now owns 42,602 shares of the biopharmaceutical company’s stock valued at $1,431,000 after acquiring an additional 5,590 shares during the period. Institutional investors own 69.36% of the company’s stock.

Pfizer, Inc. (NYSE:PFE) opened at $35.36 on Thursday. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78. The stock has a market cap of $210,889.83, a P/E ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same period in the prior year, the business earned $0.61 earnings per share. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. research analysts anticipate that Pfizer, Inc. will post 2.6 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s payout ratio is 79.01%.

A number of analysts recently weighed in on the stock. BMO Capital Markets reissued a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research note on Friday, November 10th. J P Morgan Chase & Co set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group LLC set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Finally, UBS AG set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $38.48.

COPYRIGHT VIOLATION WARNING: “Hutchinson Capital Management CA Reduces Stake in Pfizer, Inc. (PFE)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/16/hutchinson-capital-management-ca-reduces-stake-in-pfizer-inc-pfe.html.

In other news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders have sold 374,621 shares of company stock worth $12,796,098 over the last quarter. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.